^
Association details:
| Biomarker: | TNFRSF8 positive |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | McSAF 02 (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ADCs optimization lead to a significant anti-tumoral activity in lymphoma and breast tumor xenograft mouse models
Excerpt:
In the CD30-positive non-Hodgkin's lymphoma model, the MTS assay revealed similar efficacy for brentuximab vedotin and MF-BTX-MMAE (IC50 ≈ 0.1 nM) on Karpas-299 cell line. In vivo, the treatment with MF-BTX-MMAE was well tolerated at all tested doses (0.5 and 1 mg/kg). The single treatment with MF-BTX-MMAE had a marked, dose dependent, anti-tumoral efficacy with 40% and 100% of animals showing complete regression at the end of the study (9 weeks after treatment) for doses of 0.5 mg/kg and 1 mg/kg respectively.
DOI:
https://doi.org/10.1158/1538-7445.AM2020-4115
